

About OMICS Group

OMICS Group International is an amalgamation of Open Access publications and worldwide international science conferences and events. Established in the year 2007 with the sole aim of making the information on Sciences and technology 'Open Access', OMICS Group publishes 400 online open access scholarly journals in all aspects of Science, Engineering, Management and Technology journals. OMICS Group has been instrumental in taking the knowledge on Science & technology to the doorsteps of ordinary men and women. Research Scholars, Students, Libraries, Educational Institutions, Research centers and the industry are main stakeholders that benefitted greatly from this knowledge dissemination. OMICS Group also organizes 300 International conferences annually across the globe, where knowledge transfer takes place through debates, round table discussions, poster presentations, workshops, symposia and exhibitions.

About OMICS Group Conferences

OMICS Group International is a pioneer and leading science event organizer, which publishes around 400 open access journals and conducts over 300 Medical, Clinical, Engineering, Life Sciences, Pharma scientific conferences all over the globe annually with the support of more than 1000 scientific associations and 30,000 editorial board members and 3.5 million followers to its credit.

OMICS Group has organized 500 conferences, workshops and national symposiums across the major cities including San Francisco, Las Vegas, San Antonio, Omaha, Orlando, Raleigh, Santa Clara, Chicago, Philadelphia, Baltimore, United Kingdom, Valencia, Dubai, Beijing, Hyderabad, Bengaluru and Mumbai.




Novel biomarkers for diastolic heart failure

Sam Dudley, M.D., Ph.D.
Ruth and Paul Levinger Chair in Medicine
Director, Lifespan Cardiovascular Institute



- ❑ Off label uses of BH₄ discussed; Diagnostics not approved
- ❑ **Disclosure:** Inventor on provisional patents for 1) Methods of Treating Diastolic Dysfunction and Related Conditions, 13/397,622; 2) A Blood Test to Differentiate Systolic from Diastolic Heart Failure, 13/503,812

Clinical Significance of DD/DHF


- 5 million people in U.S. with Heart Failure (HF)
- ~ 1/2 of HF patients have preserved LVEF
- High morbidity and mortality in DD/DHF
- No proven treatment for patients with DD/DHF




The one kidney/DOCA/salt water model



Nephrectomy, DOCA
pellet insertion, salt
water, \pm BH₄



14 days









Model characteristics

- mild/moderate HTN
- preserved ejection fraction
- no hypertrophy
- no valvular regurgitation

- echocardiogram
- invasive hemodynamics
- tissue harvest




Hypertensive mice showed diastolic dysfunction by echocardiographic techniques




DOCA mice show abnormal hemodynamics


Baseline




EDPVR



ESPVR




LVEDP






BH₄ Improves Diastolic Function and Cardiomyocyte Relaxation



In vivo




Cellular




Glutathionylation of myosin binding protein C (MyBP-C) in diastolic dysfunction





S-Glutathionylation of cMyBP-C Correlates with Diastolic Relaxation







Cardiac myosin binding protein C (MYBPC3)



Plasma cMyBP-C-glutathionylation from DOCA-salt mice




Oxidized cMyBP-C in human blood




Asymmetric dimethyl arginine (ADMA) is lower in HFpEF


A




B



C



D



Summary

- Hypertension-induced diastolic dysfunction cardiac BH₄, increased cardiac oxidation, uncoupled nitric oxide synthase (NOS), and reduced nitric oxide (NO)
- BH₄ prevents or reverses diastolic dysfunction
- Hypertension-induced diastolic dysfunction is associated with glutathionylation of cardiac myosin binding protein C (cMyBP-C)
- Diastolic dysfunction results in elevated plasma cMyBP-C and modified cMyBP-C
- Diastolic dysfunction is associated with elevated ADMA, consistent with NOS uncoupling



Acknowledgments



■ Dudley Lab

- Hong Liu, MD, PhD
- Man Liu, PhD
- Harvey Lardin, PhD
- Josh Lovelock, MD
- Euy-Myoung Jeong, PhD
- Gad A. Silberman, MD
- Euy-Myoung Jeong, PhD
- Vikram Brahmanandam, MD
- Mihai Raicu, MS
- Song Yi Lee, MS
- Jae Hoon Chung, MD
- Cody A. Rutledge, BS
- Li Zhou, MD, PhD
- Lianzhi Gu, MD
- Qiongying Wang, MD
- Ian Greener, PhD

■ Univ. of Illinois at Chicago

- John Solaro
- Michelle M. Monasky
- Domenico M. Taglieri
- Bindiya Patel

Thanks' for your kind attention!!!!!!



Let Us Meet Again

We welcome you all to our future conferences
of OMICS Group International

Please Visit:

www.omicsgroup.com

www.conferenceseries.com

<http://cardiology.conferenceseries.com/>